ESMO World Congress on Gastrointestinal Cancer | Conference

Hepatitis C "Revolution" May Transform Liver Cancer Outcomes

July 2nd 2015

Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.

IMM-101 Active, Maintains QoL in Patients with Metastatic Pancreatic Cancer

July 2nd 2015

Investigators reported a clinically meaningful extension of overall survival with IMM-101 plus gemcitabine in patients with metastatic pancreatic cancer.

Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer

July 2nd 2015

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik fÃ¼r Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

Dr. Philip on Evofosfamide for Pancreatic Cancer

July 2nd 2015

Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses the use of the investigational drug evofosfamide for pancreatic cancer.

Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer

July 1st 2015

Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).

Low BMI Prognostic for Worse Survival in Colorectal Cancer

July 1st 2015

Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.

Dr. Zafar on Low BMI Impact on Colorectal Cancer Survival

July 1st 2015

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Dr. Arnold on a Phase III Trial Examining Options for Maintenance Therapy in mCRC

July 2nd 2014

Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).

Dr. Yoshino Discusses the Safety Profile of TAS-102

June 30th 2014

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Cetuximab, Bevacizumab Equivalent as First-Line Therapy in KRAS Wild-Type mCRC

June 28th 2014

A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.

Palliative Resection Associated With Improved Survival in mCRC

June 28th 2014

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer

June 28th 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

Dr. Venook Discusses Implications of the 80405 Study

June 28th 2014

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

TAS-102 Monotherapy Improves OS, PFS in Refractory mCRC

June 28th 2014

Treatment with the oral nucleoside TAS-102 significantly extended OS and PFS for patients with metastatic colorectal cancer refractory to standard therapies.

Dr. Wang-Gillam Discusses the NAPOLI-1 Trial in Pancreatic Cancer

June 28th 2014

Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

Active Maintenance Improves PFS in mCRC

June 28th 2014

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.

Ramucirumab Benefit for US Patients With Gastric Cancer Mirrors Global Results

June 27th 2014

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

Regorafenib Offers Effective Option for Asian Patients With mCRC

June 27th 2014

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

MM-398 Improves OS, PFS in Phase III Pancreatic Cancer Study

June 27th 2014

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.